A Delaware court ruled in favor of United Therapeutics by upholding key patent claims on inhaled dry-powder treprostinil, used to treat pulmonary hypertension associated with interstitial lung disease. Liquidia, which markets a competing drug Yutrepia, conceded infringement, causing its stock to plunge 57%, while United Therapeutics' shares rose 12.55%. The court has yet to decide on injunctions or damages, and Liquidia plans to appeal and seek FDA label changes. This ruling threatens Liquidia's main revenue source, while United Therapeutics maintains a broader product portfolio and growth prospects despite some recent setbacks.
United Therapeutics and Liquidia's patent dispute coincides with a broad downturn in the health sector on Pluang. For readers following health stocks, here is Pluang's market snapshot as of Oct 01, 2026 22:02 WIB: out of 100 priced health-sector US stocks, 25 rose and 74 fell. Notable movers include Bio-Rad Laboratories (BIO) down 3.51%, Moderna (MRNA) up 3.39%, and American Well Corp (AMWL) down 3.17%, with typical hold times ranging from 58 to 61 days and varied Pluang order activity.
Beneficient is set to report its Q3 2026 earnings on October 5, with analysts expecting $0.97 EPS and $13.1 million in revenue. The company is involved in disputes over allegedly fraudulent debt and equity claims linked to HCLP Nominees and former CE...
Robinhood Markets is broadening its platform with new features like AI-powered Robinhood Agents, crypto perpetual futures, earnings contracts, and social investing tools. The company plans to offer 24/7 trading for select U.S. stocks and ETFs, plus e...
American Battery Technology Company secured a $100 million export license from the U.S. Department of Commerce to sell recycled battery black mass, which contains critical minerals like lithium and cobalt. The company is expanding its recycling opera...
Cal-Maine Foods reported a fiscal Q1 loss of $1.26 per share, wider than the expected loss of $0.77, with revenue falling to $539.6 million, below estimates. The 42% year-over-year sales decline was driven by lower egg prices, significantly impacting...
An analyst at Truist Financial raised Wells Fargo's price target to $95, suggesting a 20.74% upside from its current price. This optimism is driven by expected strong third-quarter earnings of $1.85 per share and $22.34 billion in revenue, surpassing...
